For patients with hereditary angioedema, donidalorsen reduces the attack rate, according to a study published online May 31 in the New England Journal of Medicine to coincide with the annual congress ...

Intellia Therapeutics, Inc. NTLA announced that it has initiated the pivotal phase III HAELO study evaluating NTLA-2002 for the treatment of hereditary angioedema (HAE). The global double-blind, ...

Intellia Therapeutics, Inc. announced the dosing of the first patient in the global Phase 3 study for NTLA-2002, a CRISPR-based therapy aimed at treating hereditary angioedema (HAE). This ...

Deucrictibant significantly improved the time to onset of symptom relief, defined as PGI-C of at least “a little better”, compared with placebo (1.28 vs >12 hours). Topline data were announced from a ...

Hereditary angioedema (HAE) is a rare condition that causes fluid to build up throughout your body, triggering sudden and repeated serious swelling. This is the most common type and happens because of ...

Hereditary angioedema, known as HAE, represents one of medicine’s most perplexing conditions. This rare genetic disorder manifests through unpredictable and potentially dangerous swelling episodes ...

Good day and thank you for standing by. Welcome to the RAPIDe-3 topline data webcast. [Operator Instructions] I would now like to hand the conference over to your speaker, Maggie, please go ahead.

Angioedema is swelling in the skin. It has several causes, including allergic reactions and hereditary causes. While their symptoms are similar, knowing the underlying cause helps identify the most ...

Results showed the proportions of attacks that reached the beginning of symptom relief without a second dose were 93.9% with sebetralstat 300mg and 95.8% with sebetralstat 600mg. Oral, on-demand ...